Kanuma

In a report published Thursday, Canaccord Genuity analyst Adam Walsh, MD detailed a recent meeting with Synageva Biopharma Corp (NASDAQ: GEVA)'s management team and came away "more positive" on the LAL-D commercial opportunity. Separately, Synageva has announced that Alexion Pharmaceuticals, Inc. (...

In a report published Wednesday, Wedbush analyst David Nierengarten, Ph.D. commented on the merger agreement whereby Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) will acquire Synageva Biorpharma Corp (NASDAQ: GEVA) for $115 per share in cash and 0.6581 Alexion shares – valuing shares of Synageva at...